ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 滬
等待開盤 07-18 09:30:00 美东时间
0.0056
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 總市值 1.87万
- 52周最高 0.1498
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 總股本 334.74万
- 歷史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Analyst See It As An Emerging Biotech
Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.
07-09 03:06
D. Boral Capital Upgrades Artelo Biosciences to Buy, Announces $20 Price Target
D. Boral Capital analyst Jason Kolbert upgrades Artelo Biosciences (NASDAQ:ARTL) from Hold to Buy and announces $20 price target.
07-08 19:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
06-30 22:18
Artelo Biosciences Enters Into Definitive Securities Purchase Agreement For At-The-Market Private Placement For Gross Proceeds Of ~$1.425M
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological
06-26 20:05
D. Boral Capital Downgrades Artelo Biosciences to Hold
D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
06-11 22:29
Artelo Biosciences announces reverse stock split
Artelo Biosciences (NASDAQ:ARTL) said on Wednesday that its board has approved a 6-for-1 reverse stock split of the company’s common stock. The company’s common shares will begin trading on a split-a...
06-11 21:35
Artelo Biosciences Welcomes Publication Of Peer-Reviewed Review Highlighting Therapeutic Potential Of Fatty Acid Binding Protein Inhibitors In Treating Anxiety And Mood Disorders, Underscoring Key Roles Of FABP5, FABP3, And FABP7 In Neuroinflammation And Endocannabinoid Regulation
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological
06-02 21:05
Artelo Biosciences Q1 EPS $(0.72) Misses $(0.13) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.13) by 453.85 percent. This is a 7.69 percent increase over losses of $(0.78) per share
05-13 20:07
